Research programme: nanotechnology-based therapeutics - Ferring Pharmaceuticals

Drug Profile

Research programme: nanotechnology-based therapeutics - Ferring Pharmaceuticals

Latest Information Update: 08 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ferring Pharmaceuticals
  • Developer Ache Laboratories; Ferring Pharmaceuticals
  • Class Peptides; Proteins
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Gastrointestinal disorders

Most Recent Events

  • 30 Nov 2016 Early research in Gastrointestinal disorders in Brazil (PO)
  • 30 Nov 2016 Ferring Pharmaceuticals and Ache Laboratories enter into collaboration to develop nanotechnology-based therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top